1023595-19-8

Basic information

• Product Name: TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE
• Synonyms: TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE;tert-butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate hydrochloride;2,9-Diazaspiro[5.5]undecane-9-carboxylic acid, 1,1-dimethylethyl ester;9-diazaspiro[5.5]undecane-2-carboxylate;tert Butyl 2;1-tert-butyl-2,9-diazaspiro[5.5]undecane-2-carboxylate;2,9-Diazaspiro[5.5]undecan-9-carboxylic acid tert-butyl ester;9-Boc-2,9-diazaspiro[5.5]undecane
• CAS NO: 1023595-19-8
• Molecular Formula: C₁₄H₂₆N₂O₂
• Molecular Weight: 254.36844
• Mol File: 1023595-19-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 354.1 °C at 760 mmHg
• Flash Point: 168 °C
• Appearance: /
• Density: 1.05
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.22±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE(1023595-19-8)
• EPA Substance Registry System: TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE(1023595-19-8)

Safety Data

• Hazard Codes: F
• Statements: 11
• Safety Statements: 7-16
• TSCA: No
• Hazardous Substances Data: 1023595-19-8(Hazardous Substances Data)

Usage

Chemical Properties

white solid

Upstream product

• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 1033819-08-7 tert-butyl 4-formyl-4-propylpiperidinecarboxylate 
• 1702300-72-8 tert-butyl 4-(3-chloropropyl)-4-cyanopiperidine-1-carboxylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 

Downstream Products

• 1417839-87-2 C₂₆H₂₉F₃N₆O₃ 
• 1539283-51-6 C₁₇H₂₂F₃N₃O₂ 
• 1448753-92-1 C₂₄H₂₄F₅N₃O₃ 
• 1539284-61-1 C₁₆H₂₀F₂N₂O 
• 1448753-95-4 C₂₄H₂₄F₅N₃O₃ 
• 1452809-16-3 O₄-benzyl O₉-tert-butyl 4,9-diazaspiro[5.5]undecane-4,9-dicarboxylate 
• 1452809-21-0 benzyl 9-(isoquinolin-5-ylsulfonyl)-2,9-diazaspiro[5.5]undecane-2-carboxylate 
• 1452809-19-6 benzyl 9-(9H-purin-6-yl)-2,9-diazaspiro[5.5]undecane-2-carboxylate 
• 1086394-61-7 benzyl 2,9-diazaspiro[5.5]undecane-2-carboxylate 
• 1313802-12-8 5-(2,9-diaza-spiro[5.5]undec-2-yl)-6-methyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalene 
• 1313802-11-7 5-(2,9-diaza-spiro[5.5]undec-9-yl)-6-methyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalene 
• 1246508-28-0 (R)-tert-butyl 2-(3-(2-chlorobenzamido)-2,3-dihydro-1H-indene-5-carbonyl)-2,9-diazaspiro[5.5]undecane-9-carboxylate 
• 1257881-78-9 9-(3-(4-chlorophenoxy)benzyl)-N-(pyridin-3-yl)-2,9-diazaspiro[5.5]undecane-2-carboxamide 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases

We identified 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted ureas as highly potent soluble epoxide hydrolase (sEH) inhibitors and orally active agents for treating chronic kidney diseases. Compound 19 exhibited excellent sEH inhibitory activity a